ClinicalTrials.gg
CompletedNCT01689571CHF6001_POC2Updated Mar 30, 2017

A Study to Evaluate the Efficacy After Allergen Challenge, Safety and Tolerability of Inhaled CHF6001 DPI in Asthmatics

A Phase 2 interventional study of CHF6001 and Placebo in Asthma, sponsored by Chiesi Farmaceutici S.p.A.. Completed at 3 sites in United Kingdom. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2017-03-30.

Sponsored by Chiesi Farmaceutici S.p.A. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 81 studies in Asthma by Chiesi Farmaceutici S.p.A. — 11 open to participants now, 11 under way, 2 of them phase 3. Asthma · Chiesi Farmaceutici S.p.A..

Enrollment
49th of 66
36 · median 97
Started
2012
with 6 others
Phase 2
25 of 81
1 open now
Registered
33rd of 81
by date

Among the 81 studies in Asthma by Chiesi Farmaceutici S.p.A., this one is the 49th largest by enrollment of the 66 interventional ones that give a count, is one of 7 that started in 2012, is one of 25 in phase 2, and was the 33rd registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

11 of the 81 studies in Asthma by Chiesi Farmaceutici S.p.A. are open now, in 12 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in Asthma by Chiesi Farmaceutici S.p.A., or all of them as a file.
02

Study summary

The study is designed to look at the safety, tolerability and efficacy of 2 different doses of the study drug (CHF6001, a PDE4 inhibitor) in asthmatics, when given by inhalation, once a day for 9 days. The efficacy will be evaluated by measuring the protective effect of CHF 6001 after an allergen challenge.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • PDE4 inhibitor
  • Allergen Challenge
  • Asthma
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • written obtained
  • Non smoking or ex-smokers from at least 1 year prior to study entry
  • Males of females between 18 and 60 years inclusive
  • between 18 and 32 kg/m2
  • Ability to be trained about the proper use of the inhalation device and to perform spirometry
  • With mild to moderate allergic asthma as defined by the GINA guideline, naive
  • Atopy to at least one common aeroallergen
  • Positive allergen-induced Early Asthmatic Response and Late Asthmatic Response at screening
  • Ability to produce an adequate sputum sample
  • women, women of not or males and females of childbearing potential willing (they or their partner) to use a reliable method of .

Exclusion criteria

Exclusion Criteria:

  • Worsening of asthma or respiratory tract infection prior to study entry
  • History of life-threatening asthma or hospitalization for asthma prior to the study entry
  • Pregnant or lactating women
  • History of hypotensive episodes or fainting, dizziness or light-headedness
  • History or symptoms of clinically relevant neurologic disease
  • Symptomatic hay fever
  • Unstable concurrent disease that may impact the feasibility of the study
  • Use of systemic , nebulised bronchodilator or oral beta2-agonist
  • Use of leukotrienes modifiers, roflumilast or cromoglycate
  • Use of long acting beta2-agonist or inhaled corticosteroids
  • Use of short-acting or long-acting non-sedatives antihistamines
  • Use of any other medication for the treatment of allergic asthma other than salbutamol
  • Having received an medicinal drug within 30 days prior to study entry
  • Blood drawn of at least 250 ml in the previous 45 days
  • Ongoing use of tobacco
  • Other lung disease
  • Recent history of alcohol dependency
  • Inability to comply with the study protocol
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
36 participants (actual)

Study arms

  • Placebo comparator
    Placebo DPI

    Placebo by inhalation for 9 days

    Drug: Placebo

  • Experimental
    CHF6001 DPI Dose 2

    CHF6001 by inhalation for 9 days

    Drug: CHF6001

  • Experimental
    CHF6001 DPI Dose1

    CHF6001 by inhalation for 9 days

    Drug: CHF6001

Interventions

06

What researchers measure

Primary outcomes

  1. Allergen challenge

    Time frame: after 9 days of treatment

Secondary outcomes

  1. Induced Sputum

    Time frame: After 9 days of treatment

  2. Methacholine challenge

    Time frame: After 9 days of treatment

Other outcomes

  1. Pharmacokinetics of CHF6001 and its metabolites

    The following parameters will be evaluated at the steady state: AUC0-t, AUC0-24h, Cmax, Cmin, Cav, tmax, tmin, t½, CL/F and Vz/F

    Time frame: after 9 days of treatment

  2. Vital signs

    Time frame: After single dose and 9 days of treatment

  3. ECG

    Time frame: After single dose and 9 days of treatment

07

Study locations

3 sites
  • Hammersmith Medicines Research
    London, United Kingdom
  • Respiratory Clinical Trials
    London, United Kingdom
  • Medicines Evaluation Unit
    Manchester, United Kingdom
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2012, a primary completion of Apr 2013 and a completion of Apr 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2012
First posted
Sep 21, 2012
Start
Oct 2012
Primary completionActual
Apr 2013
CompletionActual
Apr 2013
Last update
Mar 30, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01689571
Responsible party
Sponsor
First posted
Sep 21, 2012
Start date
Oct 2012
Primary completion
Apr 2013
Completion
Apr 2013
Last update
Mar 30, 2017

Study contacts

Dave Singh, MD
principal investigator · Medicines Evaluation Unit
Brian Leaker, MD
principal investigator · Respiratory Clinical Trials
Elizabeth Tranter, MD
principal investigator · Hammersmith Medicines Research

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tanimilast

Start the discussion